Key result
Onyx Frontier stent improves deliverability over previous versions for complex lesions and HBR.
Why the study?
To review the design features, refinements, crossing profile, and deliverability of the Onyx Frontier zotarolimus-eluting stent compared with other drug-eluting stents and previous platforms.
The Onyx Frontier zotarolimus-eluting stent represents a refined device with improved deliverability suitable for complex anatomical and clinical scenarios.
May aid complex PCI in high bleeding risk patients; extends prior zotarolimus-eluting stent data but leaves open need for randomized outcomes trials.
INTRODUCTION: represents the latest iteration within the family of zotarolimus-eluting stents (ZES), designed for the treatment of coronary artery disease. Approval by the Food and Drug Administration was granted in May 2022, and Conformité Européenne marking followed in August 2022. AREAS COVERED: We hereby review the principal design features of Onyx Frontier, highlighting differences and similarities with other currently available drug-eluting stents. In addition, we focus on the refinements of this newest platform as compared with previous ZES versions, including the attributes yielding its exceptional crossing profile and deliverability. The clinical implications related to both its newest and inherited characteristics will be discussed. EXPERT OPINION: The nuances of the latest Onyx Frontier, together with the continuous refinement previously witnessed throughout the development of ZES, lead to a latest generation device ideal for a diverse spectrum of clinical and anatomical scenarios. In particular, its peculiarities will be of benefit in the settings often offered by a progressively aging population, such as high bleeding risk patients and complex coronary lesions.
No takes yet. Share an insight, caveat, or question.
Leone et al. (2023) conducted a review in coronary artery disease. Onyx Frontier drug-eluting stent vs. previous zotarolimus-eluting stents was evaluated. The Onyx Frontier zotarolimus-eluting stent features refined design and improved deliverability compared to previous versions, making it suitable for complex coronary lesions and high bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: